Inve India ▾

Supriya Lifescience share price & results

Supriya Lifescience Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Mumbai-based API manufacturer of anesthetics, anti-histamines & anti-asthmatics exported to 120+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue190 ₹ crore+31.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin25.0 %−11.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit24.0 ₹ crore−31.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity18.07 %−1.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin4.11 %+3.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)28.19 %−3.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 10 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

Supriya Lifescience Limited management guidance track record on Inve: 24 targets tracked across analysed earnings calls (5 achieved, 5 missed, 14 open).

TargetOriginal wordingSaidLatest callVerdict
Ambernath Facility Production StartStart production within the next 60 days
Call transcript, Q1 FY25 · 12 Aug 2024		Q1 FY25Q1 FY27:Successfully launched two new anesthetic liquid inhalation products from the Ambernath facility, confirming operational status.
Call transcript, Q1 FY27 · 14 Aug 2026		Achieved
Whey Protein Volume for FY26~100 metric tons
Call transcript, Q4 FY25 · 28 May 2025		Q4 FY25Q1 FY27:Promise related to FY26, which has been missed. No new updates.
Call transcript, Q1 FY27 · 14 Aug 2026		Missed
Working Capital Days Target150-160 days
Call transcript, Q4 FY25 · 28 May 2025		Q4 FY25Q1 FY27:Inventory levels are high at Rs. 230-240 crores, built up for a now-deferred maintenance plan. Liquidation will take 3-4 quarters, putting the 170-180 day target at risk.
Call transcript, Q1 FY27 · 14 Aug 2026		At Risk

Source: Inve Guidance Tracker for Supriya Lifescience Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Supriya Lifescience Limited's 24 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 21 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹850.9 +2.14% · +₹17.85

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +13.8% 1Y

₹0.6k₹0.8k₹1.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 10 Feb 2026Q4 FY26 — 27 May 2026Q1 FY27 — 14 Aug 2026

1Y: ₹747.95 on 24 Oct 2025 → ₹850.9. High ₹1,052.5 (1 Jun 2026), low ₹553.35 (23 Mar 2026).

Previous close
₹833.05
Market cap
₹6.7k Cr
52-week range
₹553.35 – ₹1,052.5
One year
+16.44%
Price to earnings (TTM to Jun 2026)
33.81×
Return on equity (TTM to Jun 2026)
18.07%

Overview

Symbol
NSE:SUPRIYA
Exchange
NSE
Currency
INR

What Supriya Lifescience Limited does

Based on the company's own presentations, annual report and earnings calls.

Supriya Lifescience Limited manufactures Active Pharmaceutical Ingredients (APIs), with a niche basket of 40+ molecules concentrated in anesthetics, anti-histamines, anti-asthmatics, anti-allergics, analgesics and vitamins, which it sells to pharmaceutical formulators, generic drugmakers and CDMO/CMO customers across 120+ countries. Its core manufacturing complex at Lote Parshuram (Ratnagiri, Maharashtra) is backward-integrated across five therapy-based blocks, with in-house synthesis of key starting materials and intermediates to secure raw-material supply and control costs. The company has also commercialised a contract-manufacturing (CMO) facility at Ambernath (Thane) that produces finished dosage forms — tablets, capsules, liquids, nasal, inhalation and injectable formulations. Two in-house R&D centres support ongoing development of new APIs, formulation lifecycle improvements and drug-delivery enhancements.

Segments

  • APIs (in-house manufacturing)
  • CMO/CDMO (contract manufacturing)
Manufacturing facility (Lote Parshuram)
35,000 sq. mt. facility with 932 KLPD reactor capacity across 5 manufacturing blocks and 9 clean rooms
Niche API portfolio
40+ APIs across anesthetics, anti-histamines, anti-asthmatics, anti-allergics, analgesics and vitamins
Country presence
120+ countries
Customer base
1,500+ customers
R&D centres
2 in-house centres (Lote R&D — lifecycle improvement; Ambernath R&D — formulations & generic APIs) staffed by a team of 68 scientists
Process patents filed (India)
4
Founded 1987Headquarters Mumbai, Maharashtra, India Company website

How the price took the results

close before → close after

Q1 FY27
−2.7%
14 Aug
Q4 FY26
+20.0%
28 May
Q3 FY26
−0.1%
10 Feb
Q2 FY26
+3.2%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Supriya Lifescience Limited

Free account: one company. Everything above stays public.

Write why you follow Supriya Lifescience Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Supriya Lifescience Limited

Guides on how to read this kind of business and the numbers that matter.